Telomir Pharmaceuticals Finalizes Proxy for Shareholder Vote on Transformative Reverse Merger

summarizeSummary

Telomir Pharmaceuticals filed its definitive proxy statement, setting the stage for a shareholder vote on March 23, 2026, for a reverse merger with TELI Pharmaceuticals, Inc. and other key corporate governance proposals.

check_boxKey Events

• Definitive Proxy Filed

  Telomir Pharmaceuticals filed its definitive additional materials proxy statement (DEFA14A) for the Annual Meeting of Shareholders scheduled for March 23, 2026.

• Reverse Merger Vote

  Shareholders will vote on the approval of a reverse merger with TELI Pharmaceuticals, Inc., which involves the issuance of shares representing over 20% of Telomir's outstanding common stock, as previously outlined in preliminary filings on January 23 and February 5, 2026.

• Corporate Governance Proposals

  Other proposals include the election of directors, ratification of the independent accounting firm, amendments to the 2023 Omnibus Incentive Plan, a reduction in the quorum requirement for shareholder meetings, and approval of option grants to non-executive board members.

auto_awesomeAnalysis

Telomir Pharmaceuticals has filed its definitive proxy statement, setting the final agenda for its Annual Meeting on March 23, 2026. The most critical proposal is the shareholder vote on a reverse merger with TELI Pharmaceuticals, Inc., which will involve issuing shares representing more than 20% of Telomir's currently outstanding common stock. This definitive filing follows preliminary proxy statements on January 23, 2026, and February 5, 2026, which initially disclosed the merger plans. This transaction is highly significant, potentially altering the company's strategic direction and capital structure, especially in light of the Nasdaq non-compliance notice received on January 12, 2026. Other notable proposals include amendments to the 2023 Omnibus Incentive Plan, a reduction in the quorum requirement for shareholder meetings, and approval of option grants to non-executive directors.